Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III

Breaks New Ground For Korean Pharma

Executive Summary

Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients. 

You may also be interested in...



Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal

With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.

How Pinotbio Is Helping Build Korea's ADC Ecosystem

Pinotbio CEO Dooyoung Jung shares his views on the Korean ADC industry’s situation and efforts needed for the sector to grow, the strengths of his company's camptothecin-based platform and pipeline, and R&D and business strategies.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel